Aulos Bioscience Reports Imneskibart-Avelumab NSCLC Trial Results
In checkpoint inhibitor-refractory adenocarcinoma non-small cell lung cancer, the regimen had median progression-free survival of 5.8 months and a confirmed objective response rate of 21%. The body text is truncated after “86% dis”.